HAX’s VC-Founder Industry Hard Tech Matchup is now accepting applications. Register today!
Back to news articles
Respiratory device startup Strados Labs bags $4.5M, looks to clinical trials
Hannah DeTavis
Strados Labs has developed a respiratory monitoring system that includes a small, cloud-connected biosensor
Strados Labs has developed a respiratory monitoring system that includes a small, cloud-connected biosensor. Source: Strados Labs

Respiratory monitoring company Strados Labs (HAX 2018) has bagged a $4.5M pre-Series A, bringing the company’s total funding to over $7M. The round was led by cultivate(MD) with participation from SOSV, Broad Street Angels, Wavemaker360 Health, and Blu Venture Investors.

Strados Labs develops a non-invasive smart device and platform that allows clinicians to remotely monitor a patient’s pulmonary state. Acting as a wearable stethoscope, the biosensor device essentially digitizes lung sounds and collects this data for a range of conditions, including COPD and asthma.

With the recent boost in funding, Strados Labs plans to expand its teams and scale its system for pharma and the clinical trials market. The COVID-19 pandemic further underscored the need for remote respiratory monitoring from home.

“We’re really excited to scale our platform for remote respiratory trials, and given the pandemic response and the huge push due to COVID, everything is happening at home,” CEO and co-founder Nick Delmonico told Technical.ly. “And we’re going right along with it.”